Journal article
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases
Amyloid, Vol.30(2), pp.161-168
06/2023
DOI: 10.1080/13506129.2022.2137400
PMID: 36282014
Abstract
This study characterised real-world treatment patterns, clinical outcomes, and cost-of-illness in patients with light-chain (AL) amyloidosis.
Data were extracted from the US-based Optum® EHR and Clinformatics® Data Mart (claims) databases (2008-2019) for patients newly diagnosed with AL amyloidosis and who initiated anti-plasma cell therapies. Healthcare resource utilisation (HCRU) and related costs were compared across lines of therapy (LOT). Incidences of cardiac and renal failure were evaluated using the Kaplan-Meier method.
About 1347 patients (EHR, n = 776; claims, n = 571) were included. Median age was 68 years; 56.8% were male. At initial diagnosis, 33.1% and 15.1% of patients had cardiac and renal failure, respectively. Most patients received bortezomib-containing treatment in LOT1 (69%); bortezomib-cyclophosphamide-dexamethasone was most common (26%). HCRU was similar across LOTs. Mean per-patient-per-month and per-patient-per-LOT costs were $19,343 and $105,944 for LOT1, $19,183 and $95,793 for LOT2, and $16,611 and $128,446 for LOT3, respectively. Costs were primarily driven by anti-plasma cell therapies, outpatient visits, and hospitalisations. The 5-year cardiac and renal failure rates following initial diagnosis were 64.5% and 39.0%, respectively.
AL amyloidosis is associated with substantial costs and suboptimal outcomes, highlighting the need for new therapeutic approaches to prevent organ deterioration, and reduce disease burden.
Details
- Title: Subtitle
- Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases
- Creators
- Angela Dispenzieri - Mayo Clinic, Rochester, MN, USAJeffrey Zonder - The Barbara Ann Karmanos Cancer InstituteJames Hoffman - Sylvester Comprehensive Cancer CenterSandra W. Wong - University of California, San FranciscoMichaela Liedtke - Stanford UniversityRafat Abonour - Indiana Cancer ConsortiumAnita D'Souza - Medical College of WisconsinCharlene Lee - Janssen (Belgium)Sarah Cote - Janssen (United States)Ravi Potluri - SmartAnalyst, Inc, New York, NY, USAEric Ammann - Janssen Global Services, Raritan, NJ, USANamPhuong TranAnnette Lam - Janssen (Belgium)Sandhya Nair - Janssen (Belgium)
- Resource Type
- Journal article
- Publication Details
- Amyloid, Vol.30(2), pp.161-168
- DOI
- 10.1080/13506129.2022.2137400
- PMID
- 36282014
- NLM abbreviation
- Amyloid
- ISSN
- 1350-6129
- eISSN
- 1744-2818
- Publisher
- Taylor & Francis
- Language
- English
- Electronic publication date
- 10/22/2022
- Date published
- 06/2023
- Academic Unit
- Epidemiology
- Record Identifier
- 9984364421002771
Metrics
13 Record Views